Risk reduction strategies for BRCA1/2 hereditary ovarian cancer syndromes: a clinical practice guideline

CONCLUSIONS: In women who harbour a pathogenic or likely pathogenic variant in BRCA1 and BRCA2 screening for ovarian cancer is not recommended. Risk-reducing surgery is recommended to reduce the risk of ovarian cancer. In the absence of contraindications, premenopausal women undergoing RRSO should be offered hormone therapy until menopause. Systemic hormone replacement therapy, is not recommended for women who have had a personal history of breast cancer. RRSO should be considered for breast cancer risk reduction in women younger than 50 years. After a breast cancer diagnosis, RRSO for breast cancer mortality reduction can be considered within two years to women who harbour a pathogenic or likely pathogenic variant in BRCA1 if younger than the recommended age range for ovarian cancer risk reduction. RRSO before the age of 40 and specifically for breast cancer treatment in BRCA2 should be considered only if recommended by their breast cancer oncologist. Following RRSO, it is not recommended to do surveillance for peritoneal cancer.PMID:34565426 | DOI:10.1186/s13053-021-00196-9
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Source Type: research

Related Links:

The cancer organization today largely reinstated its former advice that men with low-risk prostate cancer be offered active surveillance as the lone'preferred'initial treatment option.News Alerts
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
Cancer Gene Therapy, Published online: 01 December 2021; doi:10.1038/s41417-021-00402-9Correction: microRNA-let-7e in serum-derived exosomes inhibits the metastasis of non-small-cell lung cancer in a SUV39H2/LSD1/CDH1-dependent manner
Source: Cancer Gene Therapy - Category: Cancer & Oncology Authors: Source Type: research
Today's materials from the Intraclear Biologics team may be of interest to those following the development of senolytic therapies. Since the Mayo Clinic has yet to publish results from their clinical trials of fisetin as a senolytic therapy, and may not do so for a few years yet, it is good to see even preliminary data from other sources. Senolytic therapies selectively destroy senescent cells, though only one approach (the combination of dasatinib and quercetin) has been definitely shown to destroy significant numbers of senescent cells in humans. Data has yet to be published on whether fisetin performs as well in humans ...
Source: Fight Aging! - Category: Research Authors: Tags: Self-Experimentation Source Type: blogs
This study aimed to identify the clinical background and treatment outcomes of risk-reducing salpingo-oophorectomy (RRSO) in Japan for women with hereditary breast and ovarian cancer (HBOC).MethodsIn the present retrospective observational study, we examined the Japanese HBOC Consortium ’s (JHC) database. This database contains 11,711 probands who receivedBRCA genetic testing, or their relatives, with any cancer in 2433 pedigrees. This study was supported by the registration committee of the JHC.ResultsWe analyzed 488 individuals diagnosed with HBOC, of which 153 (31.4%) underwent RRSO. Of the latter patients, 88 car...
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsAmong women with an elevated risk of hereditary breast and ovarian cancer who have previously tested negative for BRCA1 and BRCA2 mutations, we propose that women with characteristics of any of the three groups above be considered for subsequent multi-gene panel testing. Additionally, ethnicity and the possibility of multiple mutations may be indications for additional testing in these women and in family members of carriers.Citation Format: Cescon DW, Ennis M, Pritchard KI, Townsley C, Warr D, Elser C, Rao L, Stambolic V, Sridhar S, Goodwin PJ. Association between BMI and residual estradiol levels in post-menop...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Poster Session Abstracts Source Type: research
(Abstracted from Hum Reprod 2016;31:1126–1132) Increased risks of female breast cancer, ovarian cancer, fallopian tube cancer, and primary peritoneal cancer have been attributed to germline mutations in the BRCA1 or BRCA2 genes. These also have an impact on ovarian reserve and fertility in women.
Source: Obstetrical and Gynecological Survey - Category: OBGYN Tags: Gynecology: Menopause Source Type: research
Purpose of reviewAs more women with an inherited increased risk of gynecologic cancer are identified, the clinician will be challenged to counsel these women on risk-reducing strategies. Recent findingsAlthough there are some recent studies that show potential for ovarian cancer surveillance strategies, there remains no definitive evidence that surveillance leads to a stage shift or a reduction in mortality. Recent studies support the following conclusions: first, oral contraceptive use reduces ovarian cancer risk without significantly increasing breast cancer risk, second, salpingo-oophorectomy leads to a reduction in ova...
Source: Current Opinion in Obstetrics and Gynecology - Category: OBGYN Tags: CANCER GENETICS: Edited by Allison W. Kurian Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Hormonal Therapy | Hormone Replacement Therapy | Hormones | Men | Menopause | Ovarian Cancer | Ovaries | Peritoneal Cancer | Study | Women